CLOVER BIO-B (02197) announced positive preliminary data from two ongoing clinical trials based on the company's proprietary and fully validated Trimer-Tag vaccine development platform, evaluating the company's PreF respiratory combination vaccine candidates (RSV+hMPV±PIV3), including:

A Phase I clinical trial conducted in Australia to evaluate respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) in head-to-head comparison with SCB-1019 (CLOVER BIO-B's RSV vaccine candidate) in elderly participants who had not previously received any RSV vaccine.

Additionally, a Phase I clinical trial conducted in the United States to evaluate head-to-head comparison of SCB-1019 (CLOVER BIO-B's RSV vaccine candidate) versus AREXVY (GSK's RSV vaccine) for booster vaccination in elderly participants who had received their initial AREXVY vaccination at least two epidemic seasons prior to enrollment.